Of note, high BAFF was associated with subclinical atherosclerosis, and it has been suggested that the anti-BAFF biologics belimumab could induce IMT decrease in SLE patients with mid-low body mass index (BMI). The gene discussed is TNFSF13B; the disease is atherosclerosis.